Literature DB >> 8112402

Cholecystokinin-8 increases K(+)-evoked [3H] gamma-aminobutyric acid release in slices from various brain areas.

M Pérez de la Mora1, A M Hernandez-Gómez, J Méndez-Franco, K Fuxe.   

Abstract

[3H] gamma-Aminobutyric acid (GABA) release was studied in rat brain slices in the absence or presence of cholecystokinin-8 (CCK-8). [3H]GABA release under the conditions used was Ca(2+)-dependent and insensitive to the presence of the glial uptake blocker beta-alanine. While the basal release of [3H]GABA was not affected by CCK-8, the K(+)-stimulated release of [3H]GABA was significantly enhanced by 300 nM of CCK-8 in the caudate putamen, the substantia nigra, the hippocampal formation and the parietofrontal cortex. In the cerebral cortex the CCK-8 enhancement of [3H]GABA release was concentration-dependent and abolished by the CCKB receptor antagonists PD135,158 (1.0 nM) and L-365,260 (100 nM). A significant counteraction of the CCK-8 action was also found with the CCKA receptor antagonist L-364,718 (100 nM) but only in concentrations at which both CCKA and CCKB receptors are blocked. No CCK-8 effects on [3H]GABA release were observed when tetrodotoxin was superfused 5 min before the K(+)-induced [3H]GABA release. It is suggested that the enhancing actions of CCK-8 on K(+)-stimulated [3H]GABA release is mainly related to an activation of CCKB receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112402     DOI: 10.1016/0014-2999(93)90029-h

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons.

Authors:  K K Miller; A Hoffer; K R Svoboda; C R Lupica
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

2.  Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.

Authors:  Sirli Raud; Jürgen Innos; Urho Abramov; Ain Reimets; Sulev Kõks; Andres Soosaar; Toshimitsu Matsui; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

3.  Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation.

Authors:  A Sebret; I Léna; D Crété; T Matsui; B P Roques; V Daugé
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

4.  Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.

Authors:  Sirli Raud; Kertu Rünkorg; Alar Veraksits; Ain Reimets; Aleksei Nelovkov; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Vallo Volke; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

5.  Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats.

Authors:  Pan-Yue Deng; Saobo Lei
Journal:  J Physiol       Date:  2006-02-02       Impact factor: 5.182

Review 6.  Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.

Authors:  Christopher L Rees; Charise M White; Giorgio A Ascoli
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

7.  Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others.

Authors:  Miranda A Karson; Kevin C Whittington; Bradley E Alger
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

8.  Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB.

Authors:  Vincent Vialou; Rosemary C Bagot; Michael E Cahill; Deveroux Ferguson; Alfred J Robison; David M Dietz; Barbara Fallon; Michelle Mazei-Robison; Stacy M Ku; Eileen Harrigan; Catherine A Winstanley; Tej Joshi; Jian Feng; Olivier Berton; Eric J Nestler
Journal:  J Neurosci       Date:  2014-03-12       Impact factor: 6.167

Review 9.  Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.

Authors:  Santiago J Ballaz; Michel Bourin
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.